Log in

Relevant bibliographies by topics / Chemotherapy role / Journal articles

Journal articles on the topic 'Chemotherapy role'

To see the other types of publications on this topic, follow the link: Chemotherapy role.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chemotherapy role.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

(R.T), Dr C. S. K. Prakash, M. D. "Nasopharyngeal Carcinoma- Role of External Beam Radiotherapy (EBRT) and Chemotherapy Vs EBRT, Chemotherapy and Intraluminal Brachytherapy." Journal of Medical Science And clinical Research 04, no. 10 (October 27, 2016): 13348–61. http://dx.doi.org/10.18535/jmscr/v4i10.92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Nithish, Dr C., Dr G. Ajith Kumar, and Dr P. Sravani. "Fishing Clues for the Efficacy of Chemotherapy: Role of Fasting." International Journal of Trend in Scientific Research and Development Volume-3, Issue-4 (June 30, 2019): 109–11. http://dx.doi.org/10.31142/ijtsrd23581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Crump, Laura. "Chemotherapy treatment — the nurse's role." Veterinary Nursing Journal 27, no. 5 (May 2012): 183–85. http://dx.doi.org/10.1111/j.2045-0648.2012.00175.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hansen, H. H. "739 The role of chemotherapy." European Journal of Cancer Supplements 1, no. 5 (September 2003): S222—S223. http://dx.doi.org/10.1016/s1359-6349(03)90767-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lind, Julena, and Nancy Jo Bush. "Nursing's role in chemotherapy administration." Seminars in Oncology Nursing 3, no. 2 (May 1987): 83–86. http://dx.doi.org/10.1016/0749-2081(87)90027-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ishikawa, Kazuhiro, Mikiyo Maeda, Yumiko Goto, Amar Gajjar, and Toshitaka Nabeshima. "Role of Pharmacists in Innovative Chemotherapy :." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 33, no. 12 (2007): 987–97. http://dx.doi.org/10.5649/jjphcs.33.987.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Aragon-Ching, JeannyB, Rita Nader, and Joelle El Amm. "Role of chemotherapy in prostate cancer." Asian Journal of Andrology 20, no. 3 (2018): 221. http://dx.doi.org/10.4103/aja.aja_40_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Paiar, Fabiola, Vanessa Di Cataldo, Giacomo Zei, Eleonora Monteleone Pasquetti, Sara Cecchini, Icro Meattini, Monica Mangoni, et al. "Role of chemotherapy in nasopharyngeal carcinoma." Oncology Reviews 6, no. 1 (June 12, 2012): 1. http://dx.doi.org/10.4081/oncol.2012.e1.

Full text

Abstract:

Nasopharyngeal carcinoma (NPC) is a unique malignant head and neck cancer with clinical, demographic, and geographic features distinct from other head and neck epithelial malignancies. Non-keratinizing, poorly differentiated, and undifferentiated WHO types 2 and 3 is the most common subtypes of NPC. NPC is also characterized by its relatively high sensitivity to radiation, so that in the last decades radiotherapy (RT) has been the cornerstone of treatment. However, in the majority of cases NPC is discovered at locally advanced stage. The results are disappointing when RT alone is offered. The 5-year survival rates have been reported to be about 34-52%. The poor prognosis for advanced NPC led to increasing interests in exploring the use of chemotherapy (CT). NPC has been considered to be not only radiosensitive but also chemo-sensitive and has shown high response rate to various chemotherapeutic agents. Certainly, the treatment strategies for NPC will continue to change and evolve as a better understanding is gained of the molecular and immune mechanisms that drive this disease. We reviewed the current literature focusing on the role of CT and new-targeted agents.

APA, Harvard, Vancouver, ISO, and other styles

9

Housley, Stephen Nick, Paul Nardelli, Allison B. Wang, Ann Marie Flores, Eric J. Perreault, and Tim Cope. "Cancer's role in chemotherapy-induced neuropathy." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e24064-e24064. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24064.

Full text

Abstract:

e24064 Background: For the constellation of neurological disorders known as chemotherapy-induced neuropathy, mechanistic understanding, and treatment remain deficient. This might be due to the fact that studies on the effects of chemotherapies on the nervous system have utilized experimental models that exclude cancer perhaps due to the presumption that chemotherapy alone explains the neuropathology. However, the convergence of cancer and chemotherapy on the same biological processes seems likely to yield non-linear interactions. This led us to hypothesize that clinically relevant neuropathy emerges from codependent actions of cancer and chemotherapy. Methods: We established a clinically-relevant animal model of chronic sensory neuropathy in rats with cancer (adenomatous polyposis coli in rat colon: Apc+/Pirc) and age-matched animals without cancer ( ApcWT) that were randomly assigned to receive a human-scaled course of oxaliplatin (OX) or control treatment (4 groups). We quantified behavioral deficits during precision ladder walking, a validated measure of locomotor performance. Neuronal signaling was measured during terminal in vivo experiments to examine the response of sensory neurons to physiologically-relevant stimuli. We defined statistical significance as when 95% of a highest density interval (HDI) of posterior probabilities do not overlap (hierarchical Bayesian modeling). Results: Apc+/Pirc+OX (n = 11) rats exhibited significantly higher error rate (19.2±5.6%, 95%HDI) during precision ladder walking in comparison to ApcWT+control (2.4±2.7%: n = 9) or Apc+/Pirc +control (2.5±2.9%: n = 7) and significantly exceeded the error rate observed in animals treated with OX alone (8.4±3.1%: n = 10). In contrast to the observations in all other groups, we found drastically impaired neuronal signaling in Apc+/Pirc+OX rats which manifested as significantly reduced sensitivity and attenuated static and dynamic firing patterns (95%HDI). Conclusions: We present the first evidence that chronic neuropathy cannot be explained by the effects of chemotherapy alone but instead depend on non-linear interactions between cancer and chemotherapy. This understanding is a prerequisite for developing meaningful treatment or prevention of neuropathy.

APA, Harvard, Vancouver, ISO, and other styles

10

Hussain, Syed A., Daniel H. Palmer, Andrea Stevens, David Spooner, Christopher J. Poole, and Daniel W. Rea. "Role of chemotherapy in breast cancer." Expert Review of Anticancer Therapy 5, no. 6 (December 2005): 1095–110. http://dx.doi.org/10.1586/14737140.5.6.1095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Thongprasert, S. "The role of chemotherapy in cholangiocarcinoma." Annals of Oncology 16 (June 2005): ii93—ii96. http://dx.doi.org/10.1093/annonc/mdi712.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Chacko, RajuTitus. "Penile carcinoma: The role of chemotherapy." Indian Journal of Urology 22, no. 4 (2006): 360. http://dx.doi.org/10.4103/0970-1591.29126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Sculier, J. P. "204 speaker ROLE OF ADJUVANT CHEMOTHERAPY." Radiotherapy and Oncology 99 (May 2011): S79—S80. http://dx.doi.org/10.1016/s0167-8140(11)70326-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bagshawe, K. D. "REVERSED-ROLE CHEMOTHERAPY FOR RESISTANT CANCER." Lancet 328, no. 8510 (October 1986): 778–81. http://dx.doi.org/10.1016/s0140-6736(86)90301-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Bagshawe, K. D. "Reversed-Role Chemotherapy for Resistant Cancer." Journal of Urology 137, no. 3 (March 1987): 589. http://dx.doi.org/10.1016/s0022-5347(17)44126-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Seam, Pamela, John E. Janik, Dan L. Longo, and Vincent T. DeVita. "Role of Chemotherapy in Hodgkin’s Lymphoma." Cancer Journal 15, no. 2 (March 2009): 150–54. http://dx.doi.org/10.1097/ppo.0b013e3181a27018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Cho, K. J., J. C. Andrews, D. M. Williams, F. Doenz, and G. E. Guy. "Hepatic arterial chemotherapy: role of angiography." Radiology 173, no. 3 (December 1989): 783–91. http://dx.doi.org/10.1148/radiology.173.3.2813787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Fitoussi, Olivier, Marc Debled, Bernard Masson, Jean-Michel Coindre, Guy Kantor, and Binh Nguyen Bui. "Advanced paraganglioma: A role for chemotherapy?" Medical and Pediatric Oncology 33, no. 2 (August 1999): 129–31. http://dx.doi.org/10.1002/(sici)1096-911x(199908)33:2<129::aid-mpo15>3.0.co;2-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Adelstein, David J. "Oropharyngeal cancer: The role of chemotherapy." Current Treatment Options in Oncology 4, no. 1 (January 2003): 3–13. http://dx.doi.org/10.1007/s11864-003-0027-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ambore, Dr Vinaya K. "A Study on Role of Neo adjuvant Chemotherapy in Locally Advanced Carcinoma of Breast." Journal of Medical Science And clinical Research 05, no. 04 (April 27, 2017): 20620–23. http://dx.doi.org/10.18535/jmscr/v5i4.144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wood, Georgina E., Helen Hockings, Danielle M. Hilton, and Stéphanie Kermorgant. "The role of MET in chemotherapy resistance." Oncogene 40, no. 11 (February 1, 2021): 1927–41. http://dx.doi.org/10.1038/s41388-020-01577-5.

Full text

Abstract:

AbstractChemotherapy remains the mainstay of treatment in the majority of solid and haematological malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and substantial research is ongoing into potential methods of overcoming this resistance. One major target, the receptor tyrosine kinase MET, has generated increasing interest with multiple clinical trials in progress. Overexpression of MET is frequently observed in a range of different cancers and is associated with poor prognosis. Studies have shown that MET promotes resistance to targeted therapies, including those targeting EGFR, BRAF and MEK. More recently, several reports suggest that MET also contributes to cytotoxic chemotherapy resistance. Here we review the preclinical evidence of MET’s role in chemotherapy resistance, the mechanisms by which this resistance is mediated and the translational relevance of MET inhibitor therapy for patients with chemotherapy resistant disease.

APA, Harvard, Vancouver, ISO, and other styles

22

Espinosa-Olarte, Paula, Anna La Salvia, Maria C. Riesco-Martinez, Beatriz Anton-Pascual, and Rocio Garcia-Carbonero. "Chemotherapy in NEN: still has a role?" Reviews in Endocrine and Metabolic Disorders 22, no. 3 (April 11, 2021): 595–614. http://dx.doi.org/10.1007/s11154-021-09638-0.

Full text

Abstract:

AbstractNeuroendocrine neoplasms (NENs) comprise a broad spectrum of tumors with widely variable biological and clinical behavior. Primary tumor site, extent of disease, tumor differentiation and expression of so matostatin receptors, proliferation and growth rates are the major prognostic factors that determine the therapeutic strategy. Treatment options for advanced disease have considerably expanded in recent years, particularly for well differentiated tumors (NETs). Novel drugs approved over the past decade in this context include somatostatin analogues and 177Lu-oxodotreotide for somatostatin-receptor-positive gastroenteropancreatic (GEP) NETs, sunitinib for pancreatic NETs (P-NETs), and everolimus for P-NETs and non-functioning lung or gastrointestinal NETs. Nevertheless, chemotherapy remains an essential component of the treatment armamentarium of patients with NENs, particularly of patients with P-NETs or those with bulky, symptomatic or rapidly progressive tumors (generally G3 or high-G2 NENs). In this manuscript we will comprehensively review available evidence related to the use of chemotherapy in lung and GEP NENs and will critically discuss its role in the treatment algorithm of this family of neoplasms.

APA, Harvard, Vancouver, ISO, and other styles

23

Nawaz, Akhtar, Hilal Matta, Alic Jacobsz, Chris Mpofu, and Ahmed Al-Salem. "Unresectable Hepatoblastoma: The Role of Preoperative Chemotherapy." Annals of Saudi Medicine 19, no. 6 (November 1999): 553–56. http://dx.doi.org/10.5144/0256-4947.1999.553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Shields, CarolL, and FairoozP Manjandavida. "The role of intravitreal chemotherapy for retinoblastoma." Indian Journal of Ophthalmology 63, no. 2 (2015): 141. http://dx.doi.org/10.4103/0301-4738.154390.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Casadei, Beatrice, Laura Nanni, Ginevra Lolli, and Pier Luigi Zinzani. "Follicular lymphoma: the diminishing role of chemotherapy." Journal of Cancer Metastasis and Treatment 8, no. 5 (2022): 21. http://dx.doi.org/10.20517/2394-4722.2022.05.

Full text

Abstract:

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, accounting for 70% of cases in Western countries. Despite this unique name, FL is an extremely heterogeneous disease, both clinically and biologically. The basis of FL heterogeneity lies in the different biological pathways which can be activated, because of the variety of gene mutations that can occur. Today, there is a growing interest in the knowledge of these activated pathways, which is also testified by the presence of a new model that incorporates FL mutations to define patient’s prognosis (m7-FLIPI). These evaluations are also appealing because of the recent possibility of using “targeted therapies”. Targeted therapies are new tools, currently applicable in the setting of relapse/refractory (R/R) disease, where we can find a great variety of “chemo-free” combinations. As in other hematologic malignancies, “cellular therapy” enriches FL drug scenario, including T-cell dependent bispecific antibodies and chimeric antigen receptor (CAR) T-cell. Since FL heterogeneity is the basis of the difference in therapeutic efficacy and disease course among patients, the hope for the future is to understand FL biology more deeply, to better comprehend how to obtain more representative samples and pre-treatment prognostic information in order to individualize the treatment strategy as early as frontline therapy

APA, Harvard, Vancouver, ISO, and other styles

26

Sun, Yue-Li, Atish Patel, Priyank Kumar, and Zhe-Sheng Chen. "Role of ABC transporters in cancer chemotherapy." Chinese Journal of Cancer 31, no. 2 (February 5, 2012): 51–57. http://dx.doi.org/10.5732/cjc.011.10466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Basilotta, Rossella, Deborah Mannino, Alessia Filippone, Giovanna Casili, Angela Prestifilippo, Lorenzo Colarossi, Gabriele Raciti, Emanuela Esposito, and Michela Campolo. "Role of Calixarene in Chemotherapy Delivery Strategies." Molecules 26, no. 13 (June 29, 2021): 3963. http://dx.doi.org/10.3390/molecules26133963.

Full text

Abstract:

Since cancer is a multifactorial disease with a high mortality rate, the study of new therapeutic strategies is one of the main objectives in modern research. Numerous chemotherapeutic agents, although widely used, have the disadvantage of being not very soluble in water or selective towards cancerous cells, with consequent side effects. Therefore, in recent years, a greater interest has emerged in innovative drug delivery systems (DDSs) such as calixarene, a third-generation supramolecular compound. Calixarene and its water-soluble derivatives show good biocompatibility and have low cytotoxicity. Thanks to their chemical–physical characteristics, calixarenes can be easily functionalized, and by itself can encapsulate host molecules forming nanostructures capable of releasing drugs in a controlled way. The encapsulation of anticancer drugs in a calixarene derivate improves their bioavailability and efficacy. Thus, the use of calixarenes as carriers of anticancer drugs could reduce their side effects and increase their affinity towards the target. This review summarizes the numerous research advances regarding the development of calixarene nanoparticles capable of encapsulating various anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

28

Lampros, Marios, Nikolaos Vlachos, Spyridon Voulgaris, and George A. Alexiou. "The Role of Hsp27 in Chemotherapy Resistance." Biomedicines 10, no. 4 (April 14, 2022): 897. http://dx.doi.org/10.3390/biomedicines10040897.

Full text

Abstract:

Heat shock protein (Hsp)-27 is a small-sized, ATP-independent, chaperone molecule that is overexpressed under conditions of cellular stress such as oxidative stress and heat shock, and protects proteins from unfolding, thus facilitating proteostasis and cellular survival. Despite its protective role in normal cell physiology, Hsp27 overexpression in various cancer cell lines is implicated in tumor initiation, progression, and metastasis through various mechanisms, including modulation of the SWH pathway, inhibition of apoptosis, promotion of EMT, adaptation of CSCs in the tumor microenvironment and induction of angiogenesis. Investigation of the role of Hsp27 in the resistance of various cancer cell types against doxorubicin, herceptin/trastuzumab, gemcitabine, 5-FU, temozolomide, and paclitaxel suggested that Hsp27 overexpression promotes cancer cell survival against the above-mentioned chemotherapeutic agents. Conversely, Hsp27 inhibition increased the efficacy of those chemotherapy drugs, both in vitro and in vivo. Although numerous signaling pathways and molecular mechanisms were implicated in that chemotherapy resistance, Hsp27 most commonly contributed to the upregulation of Akt/mTOR signaling cascade and inactivation of p53, thus inhibiting the chemotherapy-mediated induction of apoptosis. Blockage of Hsp27 could enhance the cytotoxic effect of well-established chemotherapeutic drugs, especially in difficult-to-treat cancer types, ultimately improving patients’ outcomes.

APA, Harvard, Vancouver, ISO, and other styles

29

Schiller, Joan H. "Role of Taxanes in Lung-Cancer Chemotherapy." Cancer Investigation 16, no. 7 (January 1998): 471–77. http://dx.doi.org/10.3109/07357909809011701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Viele, Carol S. "Managing oral chemotherapy: The healthcare practitioner’s role." American Journal of Health-System Pharmacy 64, no. 9_Supplement_5 (May 1, 2007): S25—S32. http://dx.doi.org/10.2146/ajhp070037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

G., McVie J. "The role of pharmacokinetics in (combination) chemotherapy." Plastic and Reconstructive Surgery 76, no. 3 (September 1985): 496. http://dx.doi.org/10.1097/00006534-198509000-00114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Shurin, Michael R. "Dual role of immunomodulation by anticancer chemotherapy." Nature Medicine 19, no. 1 (January 2013): 20–22. http://dx.doi.org/10.1038/nm.3045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Italiano, A., O. Mir, A. Cioffi, E. Palmerini, S. Piperno-Neumann, C. Perrin, L. Chaigneau, et al. "Advanced chondrosarcomas: role of chemotherapy and survival." Annals of Oncology 24, no. 11 (November 2013): 2916–22. http://dx.doi.org/10.1093/annonc/mdt374.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Loriot, Y., J. C. Soria, and T. Le Chevalier. "Expanding role of chemotherapy in lung cancer." Annals of Oncology 17 (September 2006): x101—x107. http://dx.doi.org/10.1093/annonc/mdl246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Debatin, Klaus-Michael. "The role of CD95 system in chemotherapy." Drug Resistance Updates 2, no. 2 (April 1999): 85–90. http://dx.doi.org/10.1054/drup.1999.0073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Vogelzang, Nicholas J. "Multimodality therapy in mesothelioma: role of chemotherapy." Thoracic Surgery Clinics 14, no. 4 (November 2004): 531–42. http://dx.doi.org/10.1016/j.thorsurg.2004.06.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Colombo, N. "Role of chemotherapy in relapsed ovarian cancer." Critical Reviews in Oncology/Hematology 32, no. 3 (December 1999): 221–28. http://dx.doi.org/10.1016/s1040-8428(99)00049-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

van den Bent, M. J. "The role of chemotherapy in brain metastases." European Journal of Cancer 39, no. 15 (October 2003): 2114–20. http://dx.doi.org/10.1016/s0959-8049(03)00577-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Steele, Malcolm A., and Roger M. Des Prez. "The Role of Pyrazinamide in Tuberculosis Chemotherapy." Chest 94, no. 4 (October 1988): 845–50. http://dx.doi.org/10.1378/chest.94.4.845.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bui Nguyen, Binh, Angela Cioffi, Sophie Piperno-Neumann, Loic Chaigneau, François Bertucci, Nicolas Penel, Florence Duffaud, Axel Le Cesne, and Antoine Italiano. "Advanced chondrosarcomas: Role of chemotherapy and survival." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10023. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10023.

Full text

Abstract:

10023 Background: There are no data about the role of chemotherapy in patients with advanced chondrosarcomas. Methods: From 2000 to 2011, 98 patients with a confirmed diagnosis of advanced chondrosarcomas were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 46 years (range 16-82). The most frequent histological subtype was conventional chondrosarcoma (n=60, 61%). 83 patients (85%) had metastatic disease ( lung n=71, bone n=23, liver n=6) and 15 patients (15%) had locoregional unresectable disease. 30 patients (31%) had ≥ 2 metastatic sites. 63 patients (64%) received 1st-line combination agent chemotherapy. 70 patients (71%) received a 1st-line anthracycline-containing regimen (doxorubicin + cisplatin +/- ifosfamide: n=30, doxorubicin or pegylated liposomal doxorubicin: n=18, doxorubicin + ifosfamide +/- dacarbazine: n=16, others= 6). RECIST objective response was observed in 14 patients (14%), all but two treated with anthracyclines. 30 patients (31%) had stable disease > 6 months. Median progression-free survival (PFS) and overall survival (OS) were 5.3 months (95% CI: 2.8-7.7) and 19 months (95% CI: 14-24) respectively. Performance status (PS) ≥ 2 was the sole factor significantly associated with OS. Conclusions: Chemotherapy is associated with a 6-month non-progression rate of about 45% in patients with advanced chondrosarcoma. Best supportive care should be considered in patients with poor PS. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.

APA, Harvard, Vancouver, ISO, and other styles

41

Anderson, Brian A. "Intracranial Endodermal Sinus Tumour — Role for Chemotherapy." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 14, no. 2 (May 1987): 166–71. http://dx.doi.org/10.1017/s0317167100026330.

Full text

Abstract:

Abstract:Pineal tumours are commonly of germ cell origin. The endodermal sinus tumour is a rare histologic subtype that is highly malignant and radioresistant. A single case is described and compared to six reported intracranial cases in which chemotherapy was used in addition to surgery and/or radiation. Although a beneficial effect of chemotherapy cannot be proven, the probable benefit in non-CNS cases requires that it be strongly considered. A uniform approach to diagnosis, investigation and treatment for intracranial tumours of this type is suggested.

APA, Harvard, Vancouver, ISO, and other styles

42

Olver, Ian. "Role of rolapitant in chemotherapy-induced emesis." Lancet Oncology 16, no. 9 (September 2015): 1006–7. http://dx.doi.org/10.1016/s1470-2045(15)00096-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Cardinale, Daniela, and Maria Teresa Sandri. "Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity." Progress in Cardiovascular Diseases 53, no. 2 (September 2010): 121–29. http://dx.doi.org/10.1016/j.pcad.2010.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Büchner, T., D. Urbanitz, H. Rühl, J. Fischer, and R. Kuse. "ROLE OF CHEMOTHERAPY FOR AML IN REMISSION." Lancet 325, no. 8439 (May 1985): 1224–25. http://dx.doi.org/10.1016/s0140-6736(85)92916-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Bramwell, Vivien H. C. "The role of chemotherapy in osteogenic sarcoma." Critical Reviews in Oncology/Hematology 20, no. 1-2 (August 1995): 61–85. http://dx.doi.org/10.1016/1040-8428(94)00145-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Schmitt, Jordan, and Patrick J. Loehrer. "The Role of Chemotherapy in Advanced Thymoma." Journal of Thoracic Oncology 5, no. 10 (October 2010): S357—S360. http://dx.doi.org/10.1097/jto.0b013e3181f21129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Xu, Rui-hua, and Peng Huang. "A New Role for PHD in Chemotherapy." Cancer Cell 22, no. 2 (August 2012): 143–44. http://dx.doi.org/10.1016/j.ccr.2012.07.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cavalcante, Francisco Pimentel, Eduardo C. Millen, Felipe P. Zerwes, and Guilherme G. Novita. "Role of Axillary Surgery After Neoadjuvant Chemotherapy." JCO Global Oncology, no. 6 (September 2020): 238–41. http://dx.doi.org/10.1200/jgo.19.00351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Anderson, Hudson-Peacock, and Muller. "Malignant acanthosis nigricans: potential role of chemotherapy." British Journal of Dermatology 141, no. 4 (October 1999): 714–16. http://dx.doi.org/10.1046/j.1365-2133.1999.03116.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sherman, WJ, and JJ Raizer. "Chemotherapy: what is its role in meningioma?" Expert Review of Neurotherapeutics 12, no. 10 (October 2012): 1189–96. http://dx.doi.org/10.1586/ern.12.108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!